Visit COVID-19 resources

[Skip to Content]


Response to NICE announcing their positive draft guidance for Eylea® for the treatment of macular oedema secondary to CRVO

College Statement The Royal College of Ophthalmologists welcomes the Final Appraisal Determination (FAD) from NICE recommending Eylea® (aflibercept) as a treatment option for visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). We hope that this decision will help the clinical commissioning groups to support the rapid implementation of the final